RU2644677C2 - Мсн-специфичные пептиды со смещенной рамкой считывания (псрс) для предотвращения и лечения рака - Google Patents

Мсн-специфичные пептиды со смещенной рамкой считывания (псрс) для предотвращения и лечения рака Download PDF

Info

Publication number: RU2644677C2
Authority: RU; Russia
Prior art keywords: vaccine according; peptide; mch; cancer; vaccine
Prior art date: 2012-12-13

Application number

RU2015115785A

Other languages

English (en)

Russian (ru)

Other versions

RU2015115785A (ru

Inventor

Маттиас КЛООР

Мириам РОЙШЕНБАХ

КНЕБЕЛЬ-ДЁБЕРИЦ Магнус ФОН

Original Assignee

Рупрехт-Карлс-Университэт Гейдельберг

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-13

Filing date

2012-12-13

Publication date

2018-02-13

2012-12-13 Application filed by Рупрехт-Карлс-Университэт Гейдельберг filed Critical Рупрехт-Карлс-Университэт Гейдельберг

2017-01-16 Publication of RU2015115785A publication Critical patent/RU2015115785A/ru

2018-02-13 Application granted granted Critical

2018-02-13 Publication of RU2644677C2 publication Critical patent/RU2644677C2/ru

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 44
108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 33
238000011282 treatment Methods 0.000 title claims abstract description 12
230000002265 prevention Effects 0.000 title claims abstract description 7
201000011510 cancer Diseases 0.000 title claims description 19
102000004196 processed proteins & peptides Human genes 0.000 title claims description 11
229960005486 vaccine Drugs 0.000 claims abstract description 36
208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 23
208000032818 Microsatellite Instability Diseases 0.000 claims abstract description 20
206010009944 Colon cancer Diseases 0.000 claims abstract description 19
108091007433 antigens Proteins 0.000 claims description 21
102000036639 antigens Human genes 0.000 claims description 21
239000000427 antigen Substances 0.000 claims description 20
102000004127 Cytokines Human genes 0.000 claims description 15
108090000695 Cytokines Proteins 0.000 claims description 15
238000000034 method Methods 0.000 claims description 15
239000013598 vector Substances 0.000 claims description 14
230000028993 immune response Effects 0.000 claims description 12
238000002255 vaccination Methods 0.000 claims description 10
150000007523 nucleic acids Chemical group 0.000 claims description 9
125000003275 alpha amino acid group Chemical group 0.000 claims description 8
102000019034 Chemokines Human genes 0.000 claims description 7
108010012236 Chemokines Proteins 0.000 claims description 7
230000003449 preventive effect Effects 0.000 claims description 7
230000003308 immunostimulating effect Effects 0.000 claims description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
241000710929 Alphavirus Species 0.000 claims description 5
108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
239000002671 adjuvant Substances 0.000 claims description 5
239000003550 marker Substances 0.000 claims description 5
108020004707 nucleic acids Proteins 0.000 claims description 5
102000039446 nucleic acids Human genes 0.000 claims description 5
229940023860 canarypox virus HIV vaccine Drugs 0.000 claims description 4
239000013603 viral vector Substances 0.000 claims description 4
241000700605 Viruses Species 0.000 claims description 3
239000000839 emulsion Substances 0.000 claims description 3
241000700663 Avipoxvirus Species 0.000 claims description 2
241000178270 Canarypox virus Species 0.000 claims description 2
241000702421 Dependoparvovirus Species 0.000 claims description 2
241000700618 Vaccinia virus Species 0.000 claims description 2
241000701161 unidentified adenovirus Species 0.000 claims description 2
241001430294 unidentified retrovirus Species 0.000 claims description 2
201000006082 Chickenpox Diseases 0.000 claims 1
206010046980 Varicella Diseases 0.000 claims 1
239000013600 plasmid vector Substances 0.000 claims 1
238000000746 purification Methods 0.000 claims 1
241001529453 unidentified herpesvirus Species 0.000 claims 1
210000004027 cell Anatomy 0.000 abstract description 11
210000004881 tumor cell Anatomy 0.000 abstract description 6
230000000694 effects Effects 0.000 abstract description 5
230000004044 response Effects 0.000 abstract description 5
239000000126 substance Substances 0.000 abstract description 4
239000003814 drug Substances 0.000 abstract description 2
230000001404 mediated effect Effects 0.000 abstract description 2
210000001744 T-lymphocyte Anatomy 0.000 description 24
108090000623 proteins and genes Proteins 0.000 description 15
235000001014 amino acid Nutrition 0.000 description 14
108020004414 DNA Proteins 0.000 description 12
238000002965 ELISA Methods 0.000 description 12
230000014509 gene expression Effects 0.000 description 11
150000001413 amino acids Chemical class 0.000 description 10
210000002966 serum Anatomy 0.000 description 9
101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 8
102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 8
210000000612 antigen-presenting cell Anatomy 0.000 description 8
210000003719 b-lymphocyte Anatomy 0.000 description 8
239000000969 carrier Substances 0.000 description 8
210000000987 immune system Anatomy 0.000 description 8
230000003053 immunization Effects 0.000 description 8
230000035772 mutation Effects 0.000 description 7
210000005259 peripheral blood Anatomy 0.000 description 7
239000011886 peripheral blood Substances 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 6
108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
230000006698 induction Effects 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
101000837903 Homo sapiens TATA box-binding protein-associated factor RNA polymerase I subunit B Proteins 0.000 description 5
230000024932 T cell mediated immunity Effects 0.000 description 5
102100028546 TATA box-binding protein-associated factor RNA polymerase I subunit B Human genes 0.000 description 5
230000007402 cytotoxic response Effects 0.000 description 5
239000012634 fragment Substances 0.000 description 5
230000028996 humoral immune response Effects 0.000 description 5
238000002649 immunization Methods 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
230000008439 repair process Effects 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
108060000255 AIM2 Proteins 0.000 description 4
201000009030 Carcinoma Diseases 0.000 description 4
102000008070 Interferon-gamma Human genes 0.000 description 4
108010074328 Interferon-gamma Proteins 0.000 description 4
102100024064 Interferon-inducible protein AIM2 Human genes 0.000 description 4
230000005867 T cell response Effects 0.000 description 4
230000004913 activation Effects 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
229960003130 interferon gamma Drugs 0.000 description 4
230000009257 reactivity Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
108091092878 Microsatellite Proteins 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
210000004443 dendritic cell Anatomy 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
208000015768 polyposis Diseases 0.000 description 3
230000028327 secretion Effects 0.000 description 3
101150013553 CD40 gene Proteins 0.000 description 2
108010041986 DNA Vaccines Proteins 0.000 description 2
229940021995 DNA vaccine Drugs 0.000 description 2
206010014733 Endometrial cancer Diseases 0.000 description 2
206010014759 Endometrial neoplasm Diseases 0.000 description 2
208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 2
206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
102000013462 Interleukin-12 Human genes 0.000 description 2
108010065805 Interleukin-12 Proteins 0.000 description 2
102000003816 Interleukin-13 Human genes 0.000 description 2
108090000176 Interleukin-13 Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
201000005027 Lynch syndrome Diseases 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
208000005718 Stomach Neoplasms Diseases 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
102100033254 Tumor suppressor ARF Human genes 0.000 description 2
230000030741 antigen processing and presentation Effects 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000002619 cancer immunotherapy Methods 0.000 description 2
239000005018 casein Substances 0.000 description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
235000021240 caseins Nutrition 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
210000003162 effector t lymphocyte Anatomy 0.000 description 2
206010017758 gastric cancer Diseases 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
239000003547 immunosorbent Substances 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
229940117681 interleukin-12 Drugs 0.000 description 2
238000010212 intracellular staining Methods 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229930192851 perforin Natural products 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
201000002314 small intestine cancer Diseases 0.000 description 2
201000011549 stomach cancer Diseases 0.000 description 2
238000005406 washing Methods 0.000 description 2
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical group [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
208000037051 Chromosomal Instability Diseases 0.000 description 1
PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
238000011238 DNA vaccination Methods 0.000 description 1
206010011968 Decreased immune responsiveness Diseases 0.000 description 1
238000011510 Elispot assay Methods 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
102000001398 Granzyme Human genes 0.000 description 1
108060005986 Granzyme Proteins 0.000 description 1
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
102000013691 Interleukin-17 Human genes 0.000 description 1
108050003558 Interleukin-17 Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
102000000743 Interleukin-5 Human genes 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000000704 Interleukin-7 Human genes 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
206010064912 Malignant transformation Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000710961 Semliki Forest virus Species 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
241000710960 Sindbis virus Species 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000013566 allergen Substances 0.000 description 1
229940037003 alum Drugs 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
229940024546 aluminum hydroxide gel Drugs 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000012636 effector Substances 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
-1 for example Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
210000000224 granular leucocyte Anatomy 0.000 description 1
208000021991 hereditary neoplastic syndrome Diseases 0.000 description 1
102000043557 human IFNG Human genes 0.000 description 1
229940098197 human immunoglobulin g Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000005934 immune activation Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940076144 interleukin-10 Drugs 0.000 description 1
230000004073 interleukin-2 production Effects 0.000 description 1
229940028885 interleukin-4 Drugs 0.000 description 1
229940100602 interleukin-5 Drugs 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
229940100994 interleukin-7 Drugs 0.000 description 1
201000002313 intestinal cancer Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000036212 malign transformation Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000007479 molecular analysis Methods 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
238000010606 normalization Methods 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920002627 poly(phosphazenes) Chemical class 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008458 response to injury Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
208000014680 small intestine neoplasm Diseases 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
238000013519 translation Methods 0.000 description 1
125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Mycology (AREA)
Immunology (AREA)
Microbiology (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

RU2015115785A 2012-12-13 2012-12-13 Мсн-специфичные пептиды со смещенной рамкой считывания (псрс) для предотвращения и лечения рака RU2644677C2 (ru)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP2012/005154 WO2014090265A1 (en)	2012-12-13	2012-12-13	Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer

Publications (2)

Publication Number	Publication Date
RU2015115785A RU2015115785A (ru)	2017-01-16
RU2644677C2 true RU2644677C2 (ru)	2018-02-13

Family

ID=47552936

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2015115785A RU2644677C2 (ru)	2012-12-13	2012-12-13	Мсн-специфичные пептиды со смещенной рамкой считывания (псрс) для предотвращения и лечения рака

Country Status (5)

Country	Link
KR (1)	KR101810840B1 (ko)
CN (1)	CN104853764B (ko)
BR (1)	BR112015013737B1 (ko)
RU (1)	RU2644677C2 (ko)
WO (1)	WO2014090265A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2018223093A1 (en) *	2017-06-02	2018-12-06	Arizona Board Of Regents On Behalf Of Arizona State University	Universal cancer vaccines and methods of making and using same
AU2018298849B2 (en) *	2017-07-12	2022-07-14	Nouscom Ag	A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (MSI) cancers
US12025615B2 (en)	2017-09-15	2024-07-02	Arizona Board Of Regents On Behalf Of Arizona State University	Methods of classifying response to immunotherapy for cancer
EP4038222A4 (en)	2019-10-02	2023-10-18	Arizona Board of Regents on behalf of Arizona State University	METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER
CN115916251A (zh)	2020-05-28	2023-04-04	休博治疗有限公司	肽混合物
EP4052716A1 (en)	2021-03-04	2022-09-07	Deutsches Krebsforschungszentrum - Stiftung des öffentlichen Rechts / Universität Heidelberg	Cancer therapy involving car-engineered t-cells and parvovirus h-1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003087162A2 (en) *	2002-04-18	2003-10-23	Mtm Laboratories Ag	Neopeptides and methods useful for detection and treatment of cancer
RU2424247C2 (ru) *	2005-11-30	2011-07-20	Интернэшнл Инститьют Оф Кэнсер Иммьюнолоджи, Инк.	Пептид, индуцирующий цитотоксические т-клетки (цтл), способ индукции цтл, антитело, связывающееся с этим пептидом, применение пептида в фармацевтической композиции и для лечения или предупреждения рака, антигенпредставляющая клетка

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69535036T3 (de)	1994-07-15	2011-07-07	The University of Iowa Research Foundation, IA	Immunomodulatorische oligonukleotide
ES2548391T3 (es) *	2011-09-21	2015-10-16	Ruprecht-Karls-Universität Heidelberg	Péptidos de cambio de marco (FSP) específicos de MSI para prevención y tratamiento del cáncer

2012
- 2012-12-13 KR KR1020157015802A patent/KR101810840B1/ko active IP Right Grant
- 2012-12-13 CN CN201280077683.XA patent/CN104853764B/zh active Active
- 2012-12-13 RU RU2015115785A patent/RU2644677C2/ru active
- 2012-12-13 BR BR112015013737-7A patent/BR112015013737B1/pt active IP Right Grant
- 2012-12-13 WO PCT/EP2012/005154 patent/WO2014090265A1/en active Application Filing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003087162A2 (en) *	2002-04-18	2003-10-23	Mtm Laboratories Ag	Neopeptides and methods useful for detection and treatment of cancer
RU2424247C2 (ru) *	2005-11-30	2011-07-20	Интернэшнл Инститьют Оф Кэнсер Иммьюнолоджи, Инк.	Пептид, индуцирующий цитотоксические т-клетки (цтл), способ индукции цтл, антитело, связывающееся с этим пептидом, применение пептида в фармацевтической композиции и для лечения или предупреждения рака, антигенпредставляющая клетка

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LINNEBACHER M., Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens, Int. J. Cancer, 2001,v.93, p.6-11. *
LINNEBACHER M., Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens, Int. J. Cancer, 2001,v.93, p.6-11. SCHWITALLE Y., Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells, Cancer Immunity, 2004, v.4, p.14. SCHWITALLE Y., Immune Response Against Frameshift-Induced Neopeptides in HNPCC Patients and Healthy HNPCC Mutation Carriers, Gastroenterology, 2008, v.134. *
SCHWITALLE Y., Immune Response Against Frameshift-Induced Neopeptides in HNPCC Patients and Healthy HNPCC Mutation Carriers, Gastroenterology, 2008, v.134. *
SCHWITALLE Y., Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells, Cancer Immunity, 2004, v.4, p.14. *

Also Published As

Publication number	Publication date
KR20150084060A (ko)	2015-07-21
WO2014090265A1 (en)	2014-06-19
KR101810840B1 (ko)	2017-12-20
CN104853764B (zh)	2018-06-22
BR112015013737B1 (pt)	2021-07-27
BR112015013737A2 (pt)	2017-07-11
CN104853764A (zh)	2015-08-19
RU2015115785A (ru)	2017-01-16

Publication	Publication Date	Title
US10682402B2 (en)	2020-06-16	MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
JP6916231B2 (ja)	2021-08-11	新生物ワクチン用製剤
RU2753246C2 (ru)	2021-08-12	Составы вакцин против неоплазии и способы их получения
RU2644677C2 (ru)	2018-02-13	Мсн-специфичные пептиды со смещенной рамкой считывания (псрс) для предотвращения и лечения рака
UA109891C2 (uk)	2015-10-26	Композиція пухлиноасоційованих пептидів для лікування ракових захворювань
JP2024045776A (ja)	2024-04-02	ネオ抗原およびその使用
EP2572725B1 (en)	2015-07-08	MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
AU2020366599A1 (en)	2022-06-02	Cancer vaccine
US9808504B2 (en)	2017-11-07	Immunogenic epitopes as targets for universal cancer vaccines
WO2018032501A1 (zh)	2018-02-22	一种新的肿瘤特异性多肽及其应用
JP5890769B2 (ja)	2016-03-22	がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
JP2016028025A (ja)	2016-02-25	がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
WO2018058490A1 (zh)	2018-04-05	Col14a1衍生的肿瘤抗原多肽及其应用
WO2018058489A1 (zh)	2018-04-05	Cacna1h衍生的肿瘤抗原多肽及其应用
JP2021180677A (ja)	2021-11-25	免疫療法における使用のためのポリエピトープ構築物
JP2021043204A (ja)	2021-03-18	免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定
CA2799803C (en)	2020-03-24	Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer
AU2016201986B2 (en)	2017-05-11	MSI-specific Frameshift Peptides (FSP) for Prevention and Treatment of Cancer
RU2805196C2 (ru)	2023-10-12	Неоантигены и их применение
US20150313979A1 (en)	2015-11-05	P16ink4a derived peptides for prophylaxis and therapy of hpv-associated tumors and other p16ink4a expressing tumors
Aurisicchio et al.	2011	Harnessing the immune system to fight cancer: the promise of genetic cancer vaccines
WO2002068653A2 (en)	2002-09-06	Tri-hybrid melanoma antigen
AU2002244196A1 (en)	2002-09-12	Tri-hybrid melanoma antigen